e-learning
resources
Milan 2017
Tuesday, 12.09.2017
Asthma management
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Longitudinal modeling of prebronchodilator FEV1 response to benralizumab for patients with severe asthma
L. Roskos (Gaithersburg, United States of America)
Source:
International Congress 2017 – Asthma management
Session:
Asthma management
Session type:
Thematic Poster
Number:
3968
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
L. Roskos (Gaithersburg, United States of America). Longitudinal modeling of prebronchodilator FEV1 response to benralizumab for patients with severe asthma. 3968
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Patterns of bronchodilator reversibility of FEV1 in asthma and COPD patients
Source: Annual Congress 2012 - Translational respiratory medicine in asthma and COPD
Year: 2012
Follow-up of patients with severe asthma receiving reslizumab: an FEV1 analysis
Source: International Congress 2017 – Asthma management
Year: 2017
Comparison of spirometric z-scores with FEV1 percent prediction in predicting exacerbations in elderly COPD patients
Source: International Congress 2016 – In-patient and out-patient COPD management
Year: 2016
Closing volume predicts the FEV1 response to bronchodilators in patients with COPD
Source: Virtual Congress 2020 – Advances in lung function testing
Year: 2020
Raised FeNO is associated with lower FEV1 and FEV1/FVC in children with asthma
Source: International Congress 2019 – Paediatric asthma: risk factors, biomarkers and the basics
Year: 2019
Rate of FEV1 decline by FEV1 percent predicted in UPLIFT® and TIOSPIR®
Source: International Congress 2016 – Pharmacological management of COPD
Year: 2016
Can we use pre-bronchodilator spirometry to define post-bronchodilator airflow obstruction?
Source: International Congress 2015 – Epidemiology of respiratory disease
Year: 2015
FEV6 and FEV1/FEV6 have higher association with small airway function and oxygen saturation than FVC and FEV1/FVC in patients with asthma.
Source: Virtual Congress 2020 – Lung function tests and exhaled biomarkers
Year: 2020
Omalizumab significantly improves FEV
1
in patients with severe persistent allergic asthma: a pooled analysis
Source: Eur Respir J 2005; 26: Suppl. 49, 48s
Year: 2005
Reducing the decline of FEV
1
after a 4-year therapy with montelukast in patients with bronchial asthma
Source: Annual Congress 2008 - Recent advances in the pathogenesis and treatment of asthma and COPD
Year: 2008
Changes in spirometry (FVC and FEV
1
) in a closed population of COPD patients using new standarized values for Mexican people
Source: Eur Respir J 2003; 22: Suppl. 45, 69s
Year: 2003
Maximally attained level of FEV
1
and FEV
1
decline determine airway hyperresponsiveness in adults
Source: Eur Respir J 2003; 22: Suppl. 45, 17s
Year: 2003
Baseline FEV
1
and sputum neutrophils and macrophages predict the decrease in FEV
1
after inhaled corticosteroid withdrawal in COPD
Source: Eur Respir J 2004; 24: Suppl. 48, 306s
Year: 2004
Predictions of post-bronchodilator airflow obstruction by longitudinal asthma and wheeze patterns in middle-age
Source: Virtual Congress 2021 – New evidence from longitudinal COPD cohorts and other key studies
Year: 2021
Fluctuation analysis of FEV1 in children and adolescents with controlled asthma
Source: Virtual Congress 2021 – Best of paediatric physiology and sleep research
Year: 2021
Tiotropium: COPD exacerbations and decline in FEV1
Source: Eur Respir J 2001; 18: Suppl. 33, 486s
Year: 2001
Comparative study of FEV
1
/FVC and FEV
1
/FEV
6
to screen COPD patients
Source: Eur Respir J 2005; 26: Suppl. 49, 511s
Year: 2005
Changes in FEV1 and SpO2 in patients with severe and very severe COPD
Source: Virtual Congress 2021 – Lung function testing in the management of obstructive diseases
Year: 2021
Evaluation of the response of airway obstruction to short-acting inhaled broncodilators with using FIV
1
and FEV
1
in COPD patients
Source: Eur Respir J 2005; 26: Suppl. 49, 290s
Year: 2005
FEV1 decline in occupational asthma
Source: Eur Respir J 2003; 22: Suppl. 45, 488s
Year: 2003
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept